Lauren P Wallner1, Julia R DiBello2, Bonnie H Li3, Stephen K Van Den Eeden4, Sheila Weinmann5, Debra P Ritzwoller6, Jill E Abell7, Ralph D'Agostino8, Ronald K Loo3, David S Aaronson4, Kathryn Richert-Boe5, Ralph I Horwitz9, Steven J Jacobsen3. 1. Department of Medicine, University of Michigan, Ann Arbor, MI; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. Electronic address: lwallner@med.umich.edu. 2. Worldwide Epidemiology, GlaxoSmithKline, Collegeville, PA. 3. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA. 4. Division of Research, Kaiser Permanente Northern California, Oakland, CA. 5. Center for Health Research, Kaiser Permanente Northwest, Portland, ORG. 6. Institute for Health Research, Kaiser Permanente Colorado, Denver, CO. 7. Real World Evidence, Janssen, Philadelphia, PA. 8. Department of Biostatistical Science, Wake Forest University, Winston-Salem, NC. 9. Temple University, Philadelphia, PA; Institute of Medicine, Washington, DC.
Abstract
OBJECTIVE: To compare the risk of prostate cancer mortality among men treated with 5- alpha reductase inhibitors (5-ARIs) with those treated with alpha-adrenergic blockers (ABs) in community practice settings. PATIENTS AND METHODS: A retrospective matched cohort (N=174,895) and nested case-control study (N=18,311) were conducted in 4 regions of an integrated health care system. Men 50 years and older who initiated pharmaceutical treatment for benign prostatic hyperplasia between January 1, 1992, and December 31, 2007, and had at least 3 consecutive prescriptions were followed through December 31, 2010. Adjusted subdistribution hazard ratios, accounting for competing risks of death, and matched odds ratios were used to estimate prostate cancer mortality associated with 5-ARI use (with or without concomitant ABs) as compared with AB use. RESULTS: In the cohort study, 1,053 men died of prostate cancer (mean follow-up, 3 years), 15% among 5-ARI users (N= 25,388) and 85% among AB users (N=149,507) (unadjusted mortality rate ratio, 0.80). After accounting for competing risks, it was found that 5-ARI use was not associated with prostate cancer mortality when compared with AB use (adjusted subdistribution hazard ratio, 0.85; 95% CI, 0.72-1.01). Similar results were observed in the case-control study (adjusted matched odds ratio, 0.95; 95% CI, 0.78-1.17). CONCLUSION: Among men being pharmaceutically treated for benign prostatic hyperplasia, 5-ARI use was not associated with an increased risk of prostate cancer-specific mortality when compared with AB use. The increased prevalence of high-grade lesions at the time of diagnosis noted in our study and the chemoprevention trials may not result in increased prostate cancer mortality. Copyright Â
OBJECTIVE: To compare the risk of prostate cancer mortality among men treated with 5- alpha reductase inhibitors (5-ARIs) with those treated with alpha-adrenergic blockers (ABs) in community practice settings. PATIENTS AND METHODS: A retrospective matched cohort (N=174,895) and nested case-control study (N=18,311) were conducted in 4 regions of an integrated health care system. Men 50 years and older who initiated pharmaceutical treatment for benign prostatic hyperplasia between January 1, 1992, and December 31, 2007, and had at least 3 consecutive prescriptions were followed through December 31, 2010. Adjusted subdistribution hazard ratios, accounting for competing risks of death, and matched odds ratios were used to estimate prostate cancer mortality associated with 5-ARI use (with or without concomitant ABs) as compared with AB use. RESULTS: In the cohort study, 1,053 mendied of prostate cancer (mean follow-up, 3 years), 15% among 5-ARI users (N= 25,388) and 85% among AB users (N=149,507) (unadjusted mortality rate ratio, 0.80). After accounting for competing risks, it was found that 5-ARI use was not associated with prostate cancer mortality when compared with AB use (adjusted subdistribution hazard ratio, 0.85; 95% CI, 0.72-1.01). Similar results were observed in the case-control study (adjusted matched odds ratio, 0.95; 95% CI, 0.78-1.17). CONCLUSION: Among men being pharmaceutically treated for benign prostatic hyperplasia, 5-ARI use was not associated with an increased risk of prostate cancer-specific mortality when compared with AB use. The increased prevalence of high-grade lesions at the time of diagnosis noted in our study and the chemoprevention trials may not result in increased prostate cancermortality. Copyright Â
Authors: Phyllis J Goodman; Ian M Thompson; Catherine M Tangen; John J Crowley; Leslie G Ford; Charles A Coltman Journal: J Urol Date: 2006-06 Impact factor: 7.450
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Howard L Parnes; Lori M Minasian; Paul A Godley; M Scott Lucia; Leslie G Ford Journal: N Engl J Med Date: 2013-08-15 Impact factor: 91.245
Authors: Corinna Koebnick; Annette M Langer-Gould; Michael K Gould; Chun R Chao; Rajan L Iyer; Ning Smith; Wansu Chen; Steven J Jacobsen Journal: Perm J Date: 2012
Authors: Lauren P Wallner; Julia R DiBello; Bonnie H Li; Stephen K Van Den Eeden; Sheila Weinmann; Debra P Ritzwoller; Jill E Abell; Ralph D'Agostino; Ronald K Loo; David S Aaronson; Ralph I Horwitz; Steven J Jacobsen Journal: Urology Date: 2018-06-12 Impact factor: 2.649
Authors: Jacklyn N Hellwege; Sarah Stallings; Eric S Torstenson; Robert Carroll; Kenneth M Borthwick; Murray H Brilliant; David Crosslin; Adam Gordon; George Hripcsak; Gail P Jarvik; James G Linneman; Parimala Devi; Peggy L Peissig; Patrick A M Sleiman; Hakon Hakonarson; Marylyn D Ritchie; Shefali Setia Verma; Ning Shang; Josh C Denny; Dan M Roden; Digna R Velez Edwards; Todd L Edwards Journal: Sci Rep Date: 2019-04-15 Impact factor: 4.379